成都市入境新冠病毒疫苗突破感染者特征分析  

Characteristics of SARS-CoV-2 vaccine breakthrough infections among Chinese travelers entering China via Chengdu city

作　　者：龙露 刘竹 毛毅[3] 陈恒 程悦 王亮[1,2] 罗海霞 范双凤 周觅[3] 段振华 LONG Lu;LIU Zhu;MAO Yi(Chengdu Workstation for Emerging Infectious Disease Control and Prevention,Chinese Academy of Medical Sciences,Chengdu,Sichuan Province 610041,China;不详)

机构地区：[1]中国医学科学院成都新发突发传染病防治工作站,四川成都610041 [2]成都市疾病预防控制中心 [3]成都市公共卫生临床医疗中心

出　　处：《中国公共卫生》2022年第8期990-995,共6页Chinese Journal of Public Health

基　　金：中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2020-PT330-005);中国医学科学院医学与健康科技创新工程项目(2020-12M-1-001);成都市科技局重点研发支撑计划技术创新研发项目(2020-YF05-00133-SN)。

摘　　要：目的了解新冠病毒疫苗突破感染者感染特征及其预后情况,为新冠肺炎疫情防控提供参考。方法选择2020年12月10日—2021年7月7日由成都市入境的38例中国籍新型冠状病毒(新冠病毒)感染者为研究对象,将其中14例有国产新冠病毒灭活疫苗接种史且基因分型明确的感染者作为疫苗突破感染组,将其中24例无新冠病毒疫苗接种史的感染者作为自然感染组,比较2组感染者确诊时核酸Ct值,IgM、IgG以及总抗体滴度等感染特征,入院时首次淋巴细胞计数,CD3^(+)、CD4^(+)、CD8^(+)计数等临床指标及核酸转阴时间、住院时长等预后情况方面差异。结果确诊时,疫苗突破感染组感染者新冠病毒核酸N基因Ct值(26.8±4.1)、ORF1ab基因Ct值(29.4±4.5)均明显高于自然感染组(22.4±7.4)、(24.8±6.9)(t=2.376、2.228,均P<0.05),IgM、IgG、总抗体滴度P_(50)(P_(25),P_(75))分别为0.9(0.3,11.6)、4.5(1.7,7.6)、31.9(4.6,916.4),也均明显高于自然感染组0.040(0.027,0.096)、0.006(0.003,0.052)、0.015(0.010,0.038)(均P<0.05)。疫苗突破感染组入院时首次淋巴细胞计数,CD3^(+)CD4^(+)计数、CD3^(+)CD8^(+)计数、CD3^(+)计数等指标均明显高于自然感染组(均P<0.05);嗜酸性细胞数、中性粒细胞百分比均低于自然感染组(均P<0.05)。2组感染者从确诊时核酸阳性至核酸转阴间隔时间及住院时长差异均无统计学意义(t=1.106、1.889,均P>0.05),但疫苗突破感染组住院时长<20 d的比例明显高于自然感染组(P<0.05)。结论接种新冠病毒疫苗有助于降低疫苗突破感染者体内的病毒载量,可增强感染者机体T细胞免疫反应,对感染者预后产生积极影响。Objective To investigate the characteristics and prognosis of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine breakthrough infections for providing a reference for coronavirus disease 19(COVID-19)epidemic prevention and control.Methods We collected the information on 38 SARS-CoV-2 infections laboratory-confirmed among Chinese travelers entering China via Chengdu city,Sichuan province during the period from December 10,2020 to July 7,2021 and divided the infections into a vaccine breakthrough group(14 male cases ever receiving domestic inactivated COVID-19 vaccine and with confirmed genotype of SARS-CoV-2 strains inducing the infections)and a natural infection group(18 male and 6 female cases reporting no COVID-19 vaccination history).Comparison analyses were conducted to examine differences between the two groups in epidemiological characteristics,clinical/laboratory indicators and treatment outcomes.Results The participants arrived at Chengdu from 15 foreign countries during December 10,2020–July 7,2021 and were diagnosed with SARS-CoV-2 infection within the period of December 11,2020–July 12,2021;all the participants reported no history of SARS-CoV-2 infection/nucleic acid positive before entering China.In the vaccine breakthrough group,9 participants had two doses of COVID-19 vaccine by separate inoculations with the interval of 56 days,3 had two doses in one inoculation and only 2 had one dose;the interval from the last vaccination to the confirmation of SARS-CoV-2 infection ranged 8–173 days,with a median of 100 days.No statistically significant between-group differences were observed in the distribution of age(35.0±7.7 vs.35.8±10.9 years),Pangolin-based genotyping of SARS-CoV-2 strains isolated,and the time of nucleic acid negative conversion from the first positive detection(t=1.106,P>0.05).Compared to the participants of natural infection,the participants with vaccine breakthrough infection had following significantly higher indicators:Ct value for N gene(26.8±4.1 vs.22.4±7.4)

关 键 词：疫苗突破感染 新型冠状病毒 感染特征 

分 类 号：R186[医药卫生—流行病学]